New combo therapy aims to tame leukemia without lifelong pills
NCT ID NCT07269470
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This study tests whether combining dasatinib with ropeginterferon can better control chronic myeloid leukemia in its early phase. About 40 adults newly diagnosed with CML will receive the drug pair to see if it improves disease control and reduces side effects. The goal is to manage the cancer long-term, not to cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can donor immune cells tame stem cell transplant risks?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Could bone marrow from deceased donors cure blood cancers?
- New hope for young adults with CML: asciminib under Real-World scrutiny